Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the effect of Neurexan® on the brain response when participants undergo an emotional stressful condition in verum compared to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

NCT00703885

Anxiety Disorders

COMPLETED PHASE4

Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain

NCT01128309

Generalized Anxiety Disorder

COMPLETED NA

Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment

NCT02962154

Ischemia Stress, Mental

WITHDRAWN

Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test

NCT00972985

Healthy

COMPLETED NA

Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study

NCT00491348

Worry Anxiety

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized placebo-controlled, double-blind, two-period crossover study with an explorative design. 40 healthy males aged 31-59 years will be included in the study. Participant allocation to either Neurexan® or Placebo at study start is randomized with a ratio of 1:1, i.e. 20 Neurexan® first to 20 Placebo first individuals. Participants receive totally three tablets of either Neurexan® or Placebo per treatment period orally.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Stress Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neurexan first, then Placebo

Participants received a single dose of three Neurexan tablets on trial Day 1. Following a washout period of 7 to 35 days, they received a single dose of three placebo tablets on trial Day 2.

Group Type EXPERIMENTAL

Neurexan

Intervention Type DRUG

0.6 mg / tablet

Placebo

Intervention Type DRUG

Neurexan-matched Placebo tablet

Placebo first, then Neurexan

Participants received a single dose of three Placebo tablets on trial Day 1. Following a washout period of 7 to 35 days, they received a single dose of three Neurexan tablets on trial Day 2.

Group Type EXPERIMENTAL

Neurexan

Intervention Type DRUG

0.6 mg / tablet

Placebo

Intervention Type DRUG

Neurexan-matched Placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neurexan

0.6 mg / tablet

Intervention Type DRUG

Placebo

Neurexan-matched Placebo tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nx4

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male
2. Age between ≥31 to ≤59 years
3. Fluent in German language
4. Nonsmoker
5. Able to understand the explanations and instructions given by the study physician
6. Willing to adhere to the prohibitions and restrictions specified in this protocol
7. Healthy on the basis of clinical laboratory tests, physical examination, medical history, vital signs performed at Screening Visit
8. Magnetic Resonance Imaging (MRI) compatible
9. Participants must have signed a written informed consent document prior to any study procedure indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
10. Screening Scale for Chronic Stress of the Trier Inventory for Chronic Stress (TICS-SSCS) Score ≥ 9 and ≤ 36
11. Perceived Stress Scale (PSS) \> 9

Exclusion Criteria

1. Current or past history of psychotic features or a diagnosis of any psychiatric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorder 4th edition (DSM-IV) Axis I (recurrent major depression, panic disorder, social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia and mania)
2. History of depressive episodes during the last 3 months prior to Screening Visit
3. Use of any psychotropic medication or suffering from severe psychiatric illness during the last 3 months prior to Screening Visit
4. Intake of prescription drugs for sleeping disorders or nervousness within one month prior to Screening Visit
5. Intake of over the counter (OTC) medication for the treatment of sleeping disorders or nervousness within the last (one) week prior to Screening Visit
6. High chronic stress as verified with the TICS-SSCS (\> 36)
7. Low chronic stress as verified with the TICS-SSCS (\< 9) and PSS ≤ 9
8. Participants with Blood Pressure (BP) ≥ 160/100 on day 0 and at randomization
9. Participants with treated hypertension
10. Known allergies and/or hypersensitivity to ingredients of Neurexan® (Passiflora incarnata, Avena sativa, Coffea arabica, Zincum isovalerianicum, lactose monohydrate, magnesium stearate) or Placebo (Lactose monohydrate, magnesium stearate)
11. Known Lactose intolerance
12. Use of any psychological stress-management intervention within the last 4 weeks prior to Screening Visit
13. History of substance, drug, including nicotine, or alcohol abuse within the preceding 3 months prior to Screening Visit
14. Alcohol, drug, nicotine intake within the last 24 hours before day 0 and at randomization - confirmed by positive screening tests
15. Body Mass Index (BMI) \> 30 kg/m2
16. Works regularly nights shifts
17. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic or hematologic disease as defined by clinical screening interview
18. Any somatic disease or other condition the Investigator or their duly assigned representatives believes could affect the ability of the individual to complete the study or the interpretation of the study results
19. Participants with medical illness that may have influenced brain morphology and/or physiology (e.g. uncontrolled hypertension, diabetes)
20. Participants with a history of one or more seizures without a clear and resolved aetiology
21. Participants with claustrophobia
22. Participants with tinnitus
23. Clinically significant acute illness within 7 days prior to randomization
24. Presence of metallic (ferromagnetic) implants (heart pacemaker, aneurysm clips), tattoos or piercings
25. Have received an experimental drug or used an experimental medical device (participation in any other clinical trial) within the last 30 days before study inclusion
26. Participants whose ability to speak for themselves lacks or can be doubted

Minimum Eligible Age

31 Years

Maximum Eligible Age

59 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes